跳转至内容
Merck

45706

Supelco

华法林

PESTANAL®, analytical standard

别名:

4-羟基-3-(3-氧代-1-苯基丁基)-2H-1-苯并吡喃-2-酮, 杀鼠灵钠

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H16O4
CAS号:
分子量:
308.33
Beilstein:
8868198
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

產品線

PESTANAL®

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

mp

162-164 °C (lit.)

應用

agriculture
environmental

格式

neat

SMILES 字串

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI 密鑰

PJVWKTKQMONHTI-UHFFFAOYSA-N

基因資訊

human ... VKORC1(79001)

正在寻找类似产品? 访问 产品对比指南

相关类别

應用

华法林是一种常用于预防血栓形成和血栓栓塞的抗凝剂。 其已在许多中风和肺纤维化患者研究中使用。 它已用于研究潜在风险以及与其他药物和食物的相互作用
有关合适的仪器技术的更多信息,请参阅产品的分析证书。想要获得更多支持,请联系技术服务部。

生化/生理作用

华法林由两种活性对映体R和S形式的外消旋混合物组成。 华法林比普通抗凝肝素作用慢。 华法令可抑制钙依赖性凝血因子II、VII、IX和X的生物活性形式的维生素K依赖性合成。它可抑制调节因子蛋白C、蛋白S和蛋白Z

注意

仅限于专业用户。注意 — 避免接触 — 使用前请阅读说明书。

法律資訊

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

標靶器官

Blood

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 3

1 of 3

A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
Shinji Kamisuki et al.
Journal of medicinal chemistry, 54(13), 4923-4927 (2011-05-13)
Fatostatin, a recently discovered small molecule that inhibits activation of sterol regulatory element-binding protein (SREBP), blocks biosynthesis and accumulation of fat in obese mice. We synthesized and evaluated a series of fatostatin derivatives. Our structure-activity relationships led to the identification
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
Matthew W Sherwood et al.
Circulation, 129(18), 1850-1859 (2014-02-21)
During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门